This site is intended for health professionals only

Drug maker’s growth offset by costs

teaser

Danish drug maker Novo Nordisk A/S has said that its fourth-quarter profits remained almost unchanged.

The firm, the world’s top producer of insulin, said that a 4% growth in sales was offset by higher costs.

In the last three months of 2009, the company said net profit was 2.32 billion kroner (£270.36 million). This was a drop of less than 1% from 2.33 million kroner in 2008.

Rising to 13.06 billion kroner were quarterly sales from October to December. This was up from 12.58 billion. Sales and distribution costs rose 19% to 4.23 billion kroner.

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

Shares in Novo Nordisk dropped 1.1% to 370.60 kroner (£43.18) in Copenhagen after the earnings statement had been released.

Sales rose 12% to 51.08 billion kroner, and full-year net profit was up 12% to 10.77 billion.

Chief Executive Lars Rebien Soerensen said: “We are satisfied with the solid business performance in 2009, which is primarily driven by the robust sales growth for our portfolio of modern insulins.”

Copyright Press Association 2010
Novo Nordisk A/S






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x